35.85

2.02% -0.74

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $35.85, with a volume of 503.76K. It is down -2.02% in the last 24 hours and down -6.32% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$36.59

Open:

$36.77

24h Volume:

503.76K

Relative Volume:

0.75

Market Cap:

$2.06B

Revenue:

$772.53M

Net Income/Loss:

$180.90M

P/E Ratio:

11.56

EPS:

3.1024

Net Cash Flow:

$258.73M

1W Performance:

-1.54%

1M Performance:

-6.32%

6M Performance:

+1.07%

1Y Performance:

-5.26%

1-Day Range:

$35.57

$36.96

1-Week Range:

$35.57

$38.21

52-Week Range:

$25.52

$40.87

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

268

Twitter

Next Earnings Date

2024-10-29

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	35.85	2.11B	772.53M	180.90M	258.73M	3.1024
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-26	Resumed	UBS	Neutral
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-02-25	Resumed	Oppenheimer	Outperform
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

Feb 12, 2026

Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Here's is How to Trade - Finviz

Feb 12, 2026

Feb 11, 2026

Harmony Biosciences (NASDAQ:HRMY) Receives "Neutral" Rating from UBS Group - MarketBeat

Feb 11, 2026